Close Menu

NEW YORK – Fox Chase Cancer Center and digital health startup Genome Profiling (GenPro) have partnered to identify a new immune system epigenetic biomarker to predict patient response to anti-PD1 antibody checkpoint inhibitor therapy.

Wayne, Pennsylvania-based GenPro will use its EpiMarker machine-learning platform and method to identify an interactive network of genomic DNA methylation sites in patients' circulating immune cells that may be predictive of response to therapies.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sep
30
Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.